基层医疗抗菌药物管理研究中的结局选择
本文讨论基层医疗中抗菌药物管理(AMS)研究的结局选择问题,指出临床结局与AMS结局均重要且既往试验结局指标缺乏统一标准。作者基于证据提出未来研究设计的五项建议,涵盖共同主要结局的解读、处方来源、耐药结局、干预内抗生素及患者参与。
要点
- 临床与AMS结局在基层试验中均重要,目前无统一设计标准。
- 建议共同主要结局需预先设定矛盾结果的解读规则。
- AMS效果评价应纳入常规提供者以外来源的处方。
核心结论
- 基层医疗AMS研究结局缺乏共识标准,作者提出五项设计建议以规范未来研究。
研究设计与样本
- 本文为基于既往基层医疗试验证据的论述与建议,未报告系统检索或样本量。
主要发现
- 既往基层医疗试验采用了广泛的结局测量指标,但无一致的设计标准。
- AMS干预与结局可按干预类型和目标进行描述。
关键数值与推荐
- 共同主要结局适当时,研究者应预先设定矛盾结果的解读方式。
- AMS有效性评价应确保纳入常规提供者以外来源的处方。
- 结局应尽可能包括抗菌药物耐药。
- 部分情境下可将干预内使用的抗生素纳入结局。
- 需患者参与确立优先AMS或临床结局的原则。
临床怎么用
- 设计基层AMS试验时参考五项建议选择与报告结局。
- 评价AMS效果时需覆盖非常规提供者来源的处方数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical and antimicrobial stewardship (AMS) outcomes are highly relevant to pragmatic primary care trials, reflecting aspects, such as persistent symptoms and relapses, or antibiotic use and antimicrobial resistance. Sometimes both can be equally important. We present evidence demonstrating the wide range of outcome measures used in previous primary care trials and observe that there are no agreed standards for their design. We describe AMS interventions and outcomes in terms of intervention types and targets, and we make recommendations for future research designs. Specifically, we argue that: (i) where co-primary outcomes are considered appropriate, investigators should pre-specify interpretation of conflicting results; (ii) intervention evaluation should ensure prescriptions from sources outside of the usual provider are included in any AMS effectiveness measure; (iii) where possible, outcomes should include antimicrobial resistance; (iv) in some contexts, it may be necessary to include the antibiotics used within the intervention as part of the outcome; and (v) patient involvement is needed to establish the principles investigators should use when deciding whether the AMS or clinical outcomes should be prioritized.
引用
- Gágyor I, Hay AD. Outcome selection in primary care antimicrobial stewardship research. J Antimicrob Chemother. 2021. PMID: 34542632. doi:10.1093/jac/dkab347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。